A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer

著录项

• 来源
  《Investigational New Drugs》 |2015年第1期|138-147|共10页
• 作者

  Jaafar Bennouna; Marion Deslandres; Helene Senellart; Cecile de Labareyre; Rodrigo Ruiz-Soto; Claire Wixon; Jeff Botbyl; A. Benjamin Suttle; Jean-Pierre Delord;

  展开▼
• 作者单位

  Institut de Cancérologie de l’Ouest">(1);

  Medical Oncology Department Institut Claudius Regaud IUCT-Oncopole">(2);

  Institut de Cancérologie de l’Ouest">(1);

  GlaxoSmithKline Research and Development">(3);

  GlaxoSmithKline Research and Development">(4);

  GlaxoSmithKline Research and Development">(4);

  GlaxoSmithKline Research and Development">(5);

  GlaxoSmithKline Research and Development">(5);

  Medical Oncology Department Institut Claudius Regaud IUCT-Oncopole">(2);

  Institut Claudius Regaud Département de Médecine IUCT-Oncopole">(6);

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词

  Cetuximab; Colorectal cancer; Dose-limiting toxicities; Irinotecan; Maximum tolerated dose; Pazopanib;

  机译：西妥昔单抗;大肠癌;限剂量毒性;伊立替康最大耐受剂量;帕唑帕尼;